Sofia Forstén
YOU?
Author Swipe
View article: High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia
High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia Open
Natural killer (NK) cells have proven to be safe and effective immunotherapies, associated with favorable treatment responses in chronic myeloid leukemia (CML). Augmenting NK-cell function with oncological drugs could improve NK-cell–based…
View article: Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes
Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes Open
Introduction Although immune checkpoint inhibitors (ICI) in combination with hypomethylating agents (HMA) have had limited activity in acute myeloid leukemia (AML), a subset of patients has achieved durable responses. This emphasizes the n…
View article: Tracing back primed resistance in cancer via sister cells
Tracing back primed resistance in cancer via sister cells Open
Exploring non-genetic evolution of cell states during cancer treatments has become attainable by recent advances in lineage-tracing methods. However, transcriptional changes that drive cells into resistant fates may be subtle, necessitatin…
View article: B cells rapidly target antigen and surface-derived MHCII into peripheral degradative compartments
B cells rapidly target antigen and surface-derived MHCII into peripheral degradative compartments Open
In order to mount high-affinity antibody responses, B cells internalise specific antigens and process them into peptides loaded onto MHCII for presentation to T h cells. While the biochemical principles of antigen processing and MHCII load…